Impact of comorbidities on the achievement of specific therapeutic goals in biologic‐treated asthma patients-Reference-Cited by-同舟云学术

Impact of comorbidities on the achievement of specific therapeutic goals in biologic‐treated asthma patients

Published:2024-01-05 Issue:8 Volume:79 Page:2235-2240
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Pérez de Llano Luis¹^ORCID,Urrutia Isabel²,G. Cosío Borja³^ORCID,Gullón‐Blanco José Antonio⁴,Habernau Mena Alicia⁵,Cisneros Carolina⁶,Martínez‐Moragón Eva⁷^ORCID,Marina Malanda Nuria⁸,Muñoz Esquerre Mariana⁹,Quirce Santiago¹⁰,Dacal Rivas David¹^ORCID

Affiliation:

1. Pneumology Service, Lucus Augusti University Hospital Lugo Spain

2. Pneumology Service Galdakao‐Usansolo University Hospital Galdakao Spain

3. Pneumology Service Son Espases University Hospital, IdISBa‐Ciberes Palma de Mallorca Spain

4. Pneumology Service San Agustín University Hospital Avilés Spain

5. Allergy Section, Internal Medicine Service Complejo Hospitalario de Mérida Badajoz Spain

6. Pneumology Service La Princesa University Hospital Madrid Spain

7. Pneumology Service Doctor Peset University Hospital Valencia Spain

8. Pneumology Service Cruces University Hospital Barakaldo Spain

9. Pneumology Service Bellvitge University Hospital, IBIDELL, Barcelona University Barcelona Spain

10. Department of Allergy La Paz University Hospital Madrid Spain

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.15999

Reference6 articles.

1. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

2. Factors associated with suboptimal response to monoclonal antibodies in severe asthma

3. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

4. SceloG TranTN LeTT et al.Clinical remission following biologic initiation in severe asthma. Results of the International Severe Asthma Registry (ISAR). ERS International Congress Milan Italy 9‐13 2023.

5. Association between T2‐related comorbidities and effectiveness of biologics in adult patients from the international severe asthma registry;Scelo G;Am J Respir Crit Care Med,2023